We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

99 hedge funds and large institutions have $36.1M invested in Protalix BioTherapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 9

70% more call options, than puts

Call options by funds: $651K | Put options by funds: $383K

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

35% more capital invested

Capital invested by funds: $26.8M → $36.1M (+$9.28M)

19% more funds holding

Funds holding: 83 → 99 (+16)

2.13% more ownership

Funds ownership: 18.53% → 20.66% (+2.1%)

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
28
Reduced
20
Closed
9
Calls
$651K
Puts
$383K
Net Calls
+$268K
Net Calls Change
+$287K

Top Buyers

Rank Fund Capital Flow
1
MCO
MAK Capital One
New York
+$8.79M
2
PFS
Prospera Financial Services
Texas
+$1.04M
3
State Street
State Street
Massachusetts
+$962K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$665K
5
Morgan Stanley
Morgan Stanley
New York
+$421K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$5.31M
2
Citadel Advisors
Citadel Advisors
Florida
-$788K
3
Jane Street
Jane Street
New York
-$676K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$378K
5
Barclays
Barclays
United Kingdom
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
$147K +$168K +67,893 New
OGF
27
Orin Green Financial
California
$140K +$7.45K +3,000 +5%
VFT
28
Vanguard Fiduciary Trust
Pennsylvania
$137K +$157K +63,351 New
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$117K +$45.2K +18,200 +52%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$107K +$26.2K +10,567 +27%
Invesco
31
Invesco
Georgia
$103K -$7.84K -3,161 -6%
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$99.4K +$3.59K +1,448 +3%
MIM
33
MetLife Investment Management
New Jersey
$94.8K +$108K +43,697 New
PF
34
Phoenix Financial
Israel
$86.7K +$99.3K +40,000 New
Mirae Asset Global ETFs Holdings
35
Mirae Asset Global ETFs Holdings
Hong Kong
$73.9K +$2.02K +816 +2%
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$67.5K – – –
JP Morgan Chase
37
JP Morgan Chase
New York
$66.2K +$2.01K +811 +3%
AQR Capital Management
38
AQR Capital Management
Connecticut
$66.2K +$75.7K +30,493 New
ACA
39
Aptus Capital Advisors
Alabama
$59.1K +$1.54K +621 +2%
Wells Fargo
40
Wells Fargo
California
$57.6K -$130K -52,480 -66%
CPA
41
Capital Performance Advisors
California
$56.5K +$189 +76 +0.3%
SAM
42
Smartleaf Asset Management
Massachusetts
$54.3K – – –
Simplex Trading
43
Simplex Trading
Illinois
$49.2K +$56.3K +22,671 New
SOADOR
44
State of Alaska Department of Revenue
Alaska
$47K – – –
IIM
45
INTECH Investment Management
Florida
$43.3K -$27.7K -11,175 -36%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$42.4K +$2.56K +1,030 +6%
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
$42.2K -$378K -152,311 -89%
PCM
48
Prelude Capital Management
New York
$41K -$8.3K -3,343 -15%
PFSRSONJ
49
Police & Firemen's Retirement System of New Jersey
New Jersey
$40.3K – – –
Two Sigma Investments
50
Two Sigma Investments
New York
$39.3K +$45K +18,129 New
1
2
3 4 5

PLX Hedge Fund Activity: Q1 2026 in Review

99 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2026, worth a combined $36.1M — up 35% from $26.8M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PLX positions and 9 closed out — a net gain of 18 holders — while 28 added to existing stakes and 20 trimmed.

The largest buyer was MAK Capital One, opening a new position worth an estimated $8.79M. The largest seller was Opaleye Management, cutting an estimated $5.31M.

  • 99 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2026, up from 83 in Q4 2025.
  • Funds reported $36.1M of Protalix BioTherapeutics stock for Q1 2026, up 35% quarter-over-quarter.
  • 27 funds opened new Protalix BioTherapeutics positions in Q1 2026 and 9 closed out, a net change of +18 holders.
  • The largest Protalix BioTherapeutics buyer in Q1 2026 was MAK Capital One, an estimated $8.79M added.
  • The largest Protalix BioTherapeutics seller in Q1 2026 was Opaleye Management, an estimated $5.31M sold.

Based on aggregated 13F filings for Q1 2026.